NYSE:JNJ - Johnson & Johnson Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $138.42 -0.19 (-0.14 %) (As of 05/20/2019 04:00 PM ET)Previous Close$138.61Today's Range$137.68 - $138.9652-Week Range$118.62 - $148.99Volume4.37 million shsAverage Volume6.68 million shsMarket Capitalization$371.37 billionP/E Ratio16.92Dividend Yield2.60%Beta0.67 ProfileAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular diseases; sterilization and disinfection products to reduce surgical infection; diabetes care products; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. It has research and collaboration alliance with Morphic Therapeutic. The company was incorporated in 1887 and is based in New Brunswick, New Jersey. Receive JNJ News and Ratings via Email Sign-up to receive the latest news and ratings for JNJ and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNYSE:JNJ Previous Symbol CUSIP47816010 CIK200406 Webwww.jnj.com Phone732-524-0400Debt Debt-to-Equity Ratio0.47 Current Ratio1.44 Quick Ratio1.13Price-To-Earnings Trailing P/E Ratio16.92 Forward P/E Ratio16.10 P/E Growth2.4 Sales & Book Value Annual Sales$81.58 billion Price / Sales4.55 Cash Flow$10.8821 per share Price / Cash Flow12.72 Book Value$21.97 per share Price / Book6.30Profitability EPS (Most Recent Fiscal Year)$8.18 Net Income$15.30 billion Net Margins17.99% Return on Equity36.29% Return on Assets14.55%Miscellaneous Employees135,100 Outstanding Shares2,682,902,000Market Cap$371.37 billion Next Earnings Date7/16/2019 (Estimated) OptionableOptionable Johnson & Johnson (NYSE:JNJ) Frequently Asked Questions What is Johnson & Johnson's stock symbol? Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ." How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson? Johnson & Johnson declared a quarterly dividend on Thursday, April 25th. Investors of record on Tuesday, May 28th will be given a dividend of $0.95 per share on Tuesday, June 11th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.75%. The ex-dividend date of this dividend is Friday, May 24th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $0.90. View Johnson & Johnson's Dividend History. How will Johnson & Johnson's stock buyback program work? Johnson & Johnson declared that its Board of Directors has authorized a stock buyback program on Monday, December 17th 2018, which authorizes the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 1.5% of its shares through open market purchases. Shares buyback programs are generally an indication that the company's board believes its stock is undervalued. How were Johnson & Johnson's earnings last quarter? Johnson & Johnson (NYSE:JNJ) issued its earnings results on Tuesday, April, 16th. The company reported $2.10 earnings per share for the quarter, topping the consensus estimate of $2.03 by $0.07. The business had revenue of $20.02 billion for the quarter, compared to the consensus estimate of $19.55 billion. Johnson & Johnson had a net margin of 17.99% and a return on equity of 36.29%. The firm's revenue was up .1% compared to the same quarter last year. During the same period last year, the firm posted $2.06 earnings per share. View Johnson & Johnson's Earnings History. When is Johnson & Johnson's next earnings date? Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, July 16th 2019. View Earnings Estimates for Johnson & Johnson. How can I listen to Johnson & Johnson's earnings call? Johnson & Johnson will be holding an earnings conference call on Tuesday, July 16th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. What guidance has Johnson & Johnson issued on next quarter's earnings? Johnson & Johnson issued an update on its FY19 earnings guidance on Tuesday, April, 16th. The company provided earnings per share (EPS) guidance of $8.53-8.63 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.59. The company issued revenue guidance of $80.4-81.2 billion, compared to the consensus revenue estimate of $81.17 billion.Johnson & Johnson also updated its FY 2019 guidance to $8.53-8.63 EPS. What price target have analysts set for JNJ? 11 brokerages have issued 1-year price targets for Johnson & Johnson's stock. Their predictions range from $129.00 to $157.00. On average, they anticipate Johnson & Johnson's stock price to reach $146.4444 in the next year. This suggests a possible upside of 5.8% from the stock's current price. View Analyst Price Targets for Johnson & Johnson. What is the consensus analysts' recommendation for Johnson & Johnson? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 5 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Johnson & Johnson. Has Johnson & Johnson been receiving favorable news coverage? Press coverage about JNJ stock has been trending somewhat negative recently, according to InfoTrie. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Johnson & Johnson earned a media sentiment score of -1.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an impact on the company's share price in the near term. Who are some of Johnson & Johnson's key competitors? Some companies that are related to Johnson & Johnson include Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), AbbVie (ABBV), Novo Nordisk A/S (NVO), Eli Lilly And Co (LLY), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Celgene (CELG), Bayer (BAYRY) and Shire (SHPG). What other stocks do shareholders of Johnson & Johnson own? Based on aggregate information from My MarketBeat watchlists, some companies that other Johnson & Johnson investors own include AT&T (T), Verizon Communications (VZ), Cisco Systems (CSCO), Exxon Mobil (XOM), Pfizer (PFE), Intel (INTC), JPMorgan Chase & Co. (JPM), Procter & Gamble (PG), Walt Disney (DIS) and General Electric (GE). Who are Johnson & Johnson's key executives? Johnson & Johnson's management team includes the folowing people: Mr. Alex Gorsky, Chairman & CEO (Age 59)Mr. Joseph J. Wolk CPA, Exec. VP & CFO (Age 52)Dr. Paulus A. Stoffels, Chief Scientific Officer (Age 57)Mr. Michael H. Ullmann, Exec. VP & Gen. Counsel (Age 60)Mr. Joaquin Duato, Vice Chairman of Exec. Committee (Age 56) Who are Johnson & Johnson's major shareholders? Johnson & Johnson's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.04%), Geode Capital Management LLC (1.34%), Northern Trust Corp (1.30%), Wellington Management Group LLP (0.89%), Morgan Stanley (0.74%) and FMR LLC (0.67%). Company insiders that own Johnson & Johnson stock include Alex Gorsky, Charles Prince, Dominic J Caruso, Joaquin Duato, Michael E Sneed, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson. Which institutional investors are selling Johnson & Johnson stock? JNJ stock was sold by a variety of institutional investors in the last quarter, including Sanders Capital LLC, FMR LLC, Morgan Stanley, Amundi Pioneer Asset Management Inc., LSV Asset Management, Confluence Investment Management LLC, Voya Investment Management LLC and FIL Ltd. Company insiders that have sold Johnson & Johnson company stock in the last year include Alex Gorsky, Joaquin Duato, Michael E Sneed, Peter Fasolo and Ronald A Kapusta. View Insider Buying and Selling for Johnson & Johnson. Which institutional investors are buying Johnson & Johnson stock? JNJ stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Ronna Sue Cohen, Renaissance Technologies LLC, Ellis Investment Partners LLC, Nordea Investment Management AB, Railway Pension Investments Ltd, DekaBank Deutsche Girozentrale and California Public Employees Retirement System. View Insider Buying and Selling for Johnson & Johnson. How do I buy shares of Johnson & Johnson? Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Johnson & Johnson's stock price today? One share of JNJ stock can currently be purchased for approximately $138.42. How big of a company is Johnson & Johnson? Johnson & Johnson has a market capitalization of $371.37 billion and generates $81.58 billion in revenue each year. The company earns $15.30 billion in net income (profit) each year or $8.18 on an earnings per share basis. Johnson & Johnson employs 135,100 workers across the globe. What is Johnson & Johnson's official website? The official website for Johnson & Johnson is http://www.jnj.com. How can I contact Johnson & Johnson? Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at 732-524-0400. MarketBeat Community Rating for Johnson & Johnson (NYSE JNJ)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 729 (Vote Outperform)Underperform Votes: 824 (Vote Underperform)Total Votes: 1,553MarketBeat's community ratings are surveys of what our community members think about Johnson & Johnson and other stocks. Vote "Outperform" if you believe JNJ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNJ will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/20/2019 by MarketBeat.com StaffFeatured Article: Average Daily Trade Volume - What You Need to Know Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.